A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects
暂无分享,去创建一个
Jie Zhang | Jie Zhang | Min Li | Chengyuan Liang | Lei Tian | Zhenfeng Shi | Min Li | Xiaodong Ren | Liang Xin
[1] Yulin Zhang,et al. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa , 2022, Microbiology spectrum.
[2] R. Kale,et al. Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection. , 2021, Bioorganic & medicinal chemistry letters.
[3] Sheridan M. Hoy. Contezolid: First Approval , 2021, Drugs.
[4] Arnold Lee. Ibrexafungerp: First Approval , 2021, Drugs.
[5] Qianqian Zhao,et al. Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs. , 2021, Journal of medicinal chemistry.
[6] A. Scala,et al. Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects , 2021, Molecules.
[7] R. Chai,et al. Mechanism and Prevention of Ototoxicity Induced by Aminoglycosides , 2021, Frontiers in Cellular Neuroscience.
[8] R. Echols,et al. Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’ , 2021, Clinical Drug Investigation.
[9] A. Atilgan,et al. A trimethoprim derivative impedes antibiotic resistance evolution , 2021, Nature Communications.
[10] H. Bax,et al. New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis , 2021, Journal of clinical medicine.
[11] Raj Kumar,et al. U.S. FDA Approved Drugs from 2015-June 2020: A Perspective. , 2021, Journal of medicinal chemistry.
[12] X. Hou,et al. Nanohole-boosted electron transport between nanomaterials and bacteria as a concept for nano–bio interactions , 2021, Nature communications.
[13] P. Cos,et al. The search for novel treatment strategies for Streptococcus pneumoniae infections , 2021, FEMS microbiology reviews.
[14] L. Mandell,et al. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia , 2020, Drugs.
[15] F. Kong,et al. Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study , 2020, BMC microbiology.
[16] N. Razzaghi-Asl,et al. Synthesis and biological assessment of ciprofloxacin-derived 1,3,4-thiadiazoles as anticancer agents. , 2020, Bioorganic chemistry.
[17] W. Ang,et al. “Illuminating” Echinocandins’ Mechanism of Action , 2020, ACS central science.
[18] I. Lomakin,et al. Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome , 2020, Proceedings of the National Academy of Sciences.
[19] Shengzheng Wang,et al. Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall. , 2020, Journal of medicinal chemistry.
[20] T. Velkov,et al. Structure-activity relationships of daptomycin lipopeptides. , 2020, Journal of medicinal chemistry.
[21] A. Velayati,et al. Caspofungin: a review of its characteristics, activity, and use in intensive care units , 2020, Expert review of anti-infective therapy.
[22] S. Singh,et al. Lascufloxacin hydrochloride to treat bacterial infection. , 2020, Drugs of today.
[23] A. Rubio,et al. In Vitro and In Vivo Characterization of Tebipenem, an Oral Carbapenem , 2020, Antimicrobial Agents and Chemotherapy.
[24] T. Lithgow,et al. Characterization of the Core Ribosomal Binding Region for the Oxazolidone Family of Antibiotics Using Cryo-EM. , 2020, ACS pharmacology & translational science.
[25] Karthik Gunasekaran,et al. Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital. , 2020, The Journal of antimicrobial chemotherapy.
[26] Li Li,et al. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients. , 2020, Clinical therapeutics.
[27] R. Montelaro,et al. Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria , 2020, Science Advances.
[28] H. Sahl,et al. Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids , 2020, Nature Communications.
[29] M. Chorilli,et al. Biological Properties and Analytical Methods for Micafungin: A Critical Review , 2020, Critical reviews in analytical chemistry.
[30] M. Bassetti,et al. The interplay between acute bacterial skin and skin structure infections and depression: a vicious circle of major clinical importance. , 2020, Current opinion in infectious diseases.
[31] Denice C. Bay,et al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent , 2020, Drugs.
[32] R. Grimalt,et al. Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents , 2020, Dermatology.
[33] Guang-Ji Wang,et al. Mechanisms and pharmacokinetic/pharmacodynamic profiles underlying the low nephrotoxicity and ototoxicity of etimicin , 2020, Acta Pharmacologica Sinica.
[34] G. Zhanel,et al. A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development , 2020, Antimicrobial Agents and Chemotherapy.
[35] J. Tour,et al. Molecular Nanomachines Disrupt Bacterial Cell Wall, Increasing Sensitivity of Extensively Drug-Resistant Klebsiella pneumoniae to Meropenem , 2019, ACS nano.
[36] R. Echols,et al. Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] K. Kazmierczak,et al. In vitro activity of imipenem-relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017. , 2019, International journal of antimicrobial agents.
[38] B. Wilkinson,et al. Antibiotics: past, present and future. , 2019, Current opinion in microbiology.
[39] H. A. Farrag,et al. Natural outer membrane permeabilizers boost antibiotic action against irradiated resistant bacteria , 2019, Journal of Biomedical Science.
[40] R. Bonomo,et al. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. , 2019, The Journal of antimicrobial chemotherapy.
[41] Xiaojie Li,et al. Coagulation factors VII, IX and X are effective antibacterial proteins against drug-resistant Gram-negative bacteria , 2019, Cell Research.
[42] P. Eckburg,et al. Omadacycline for Acute Bacterial Skin and Skin Structure Infections , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] J. Marty,et al. Optical and Electrochemical Sensors and Biosensors for the Detection of Quinolones. , 2019, Trends in biotechnology.
[44] Milad Iranshahy,et al. Review on plant antimicrobials: a mechanistic viewpoint , 2019, Antimicrobial Resistance & Infection Control.
[45] C. Chao,et al. The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials , 2019, Journal of clinical medicine.
[46] M. McCarthy. Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline , 2019, Clinical Pharmacokinetics.
[47] Durães,et al. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines , 2019, Pharmaceuticals.
[48] Hongfen Yang,et al. Recent Progress in Natural-Product-Inspired Programs Aimed To Address Antibiotic Resistance and Tolerance. , 2019, Journal of medicinal chemistry.
[49] Jian Sun,et al. A Genomic, Evolutionary, and Mechanistic Study of MCR‐5 Action Suggests Functional Unification across the MCR Family of Colistin Resistance , 2019, Advanced science.
[50] K. Rodvold. Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin , 2019, The Journal of antimicrobial chemotherapy.
[51] S. Gelone,et al. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia , 2019, The Journal of antimicrobial chemotherapy.
[52] J. Vila,et al. Ozenoxacin: a review of preclinical and clinical efficacy , 2019, Expert review of anti-infective therapy.
[53] P. Eckburg,et al. Omadacycline for Community‐Acquired Bacterial Pneumonia , 2019, The New England journal of medicine.
[54] J. Karlowsky,et al. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli , 2019, Drugs.
[55] E. Deeks. Sarecycline: First Global Approval , 2019, Drugs.
[56] A. Mehta,et al. Cutaneous Complications in Recipients of Lung Transplants: A Pictorial Review. , 2019, Chest.
[57] B. Sankaran,et al. Differential active site requirements for NDM-1 β-lactamase hydrolysis of carbapenem versus penicillin and cephalosporin antibiotics , 2018, Nature Communications.
[58] S. Flanagan,et al. Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid Phosphate , 2018, Antimicrobial Agents and Chemotherapy.
[59] R. Hall,et al. An evaluation of tedizolid for the treatment of MRSA infections , 2018, Expert opinion on pharmacotherapy.
[60] A. Mankin,et al. How Macrolide Antibiotics Work. , 2018, Trends in biochemical sciences.
[61] M. Veve,et al. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic , 2018, Pharmacotherapy.
[62] Li Cai,et al. Crystal structure of tebipenem pivoxil , 2018, Acta crystallographica. Section E, Crystallographic communications.
[63] Sohita Dhillon. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections , 2018, Drugs.
[64] M. Pucci,et al. Tebipenem, the first oral carbapenem antibiotic , 2018, Expert review of anti-infective therapy.
[65] T. Wencewicz,et al. Tetracycline-Inactivating Enzymes , 2018, Front. Microbiol..
[66] P. Stogios,et al. Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes. , 2018, ACS infectious diseases.
[67] R. Ebright,et al. Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3). , 2018, Molecular cell.
[68] S. Paukner,et al. In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens , 2018, Antimicrobial Agents and Chemotherapy.
[69] A. Cheng,et al. Mind Your Ears: A New Antidote to Aminoglycoside Toxicity? , 2018, Journal of medicinal chemistry.
[70] Kevin Braeckmans,et al. Nanomaterials and molecular transporters to overcome the bacterial envelope barrier: Towards advanced delivery of antibiotics , 2017, Advanced drug delivery reviews.
[71] A. Minami,et al. Biosynthetic Machinery of Diterpene Pleuromutilin Isolated from Basidiomycete Fungi , 2017, Chembiochem : a European journal of chemical biology.
[72] M. Hackel,et al. In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae , 2017, Antimicrobial Agents and Chemotherapy.
[73] A. Caffrey,et al. Thrombocytopenia with Tedizolid and Linezolid , 2017, Antimicrobial Agents and Chemotherapy.
[74] Tianfeng Chen,et al. Modified Penicillin Molecule with Carbapenem-Like Stereochemistry Specifically Inhibits Class C β-Lactamases , 2017, Antimicrobial Agents and Chemotherapy.
[75] R. MacLaren,et al. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study , 2017, Annals of Clinical Microbiology and Antimicrobials.
[76] A. Markham. Delafloxacin: First Global Approval , 2017, Drugs.
[77] M. Hackel,et al. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study) , 2017, Antimicrobial Agents and Chemotherapy.
[78] D. Fairlie,et al. Orally Absorbed Cyclic Peptides. , 2017, Chemical reviews.
[79] M. El-Gamal,et al. Recent updates of carbapenem antibiotics. , 2017, European journal of medicinal chemistry.
[80] I. Schalk,et al. Bacterial Iron Uptake Pathways: Gates for the Import of Bactericide Compounds. , 2017, Journal of medicinal chemistry.
[81] M. Richards,et al. Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei , 2017, Antimicrobial Agents and Chemotherapy.
[82] Yahong Liu,et al. Design, synthesis and antibacterial evaluation of novel pleuromutilin derivatives possessing piperazine linker. , 2017, European journal of medicinal chemistry.
[83] D. Andes,et al. In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model , 2017, Antimicrobial Agents and Chemotherapy.
[84] Ximing Xu,et al. Synthesis and antibacterial activities of novel pleuromutilin derivatives with a substituted pyrimidine moiety. , 2017, European journal of medicinal chemistry.
[85] H. Schweizer,et al. Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance , 2016, The Journal of antimicrobial chemotherapy.
[86] L. Scott. Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia , 2016, Drugs.
[87] H. Yoshizawa,et al. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa , 2016, Antimicrobial Agents and Chemotherapy.
[88] Sungkyoung Lee,et al. Fluoroquinolone resistance of Streptococcus pneumoniae isolates causing invasive disease: special focus on zabofloxacin. , 2016, Diagnostic microbiology and infectious disease.
[89] Ronald N. Jones,et al. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae , 2016, Antimicrobial Agents and Chemotherapy.
[90] D. Szabo,et al. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin , 2016, Annals of Clinical Microbiology and Antimicrobials.
[91] R. Bonomo,et al. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? , 2016, Expert opinion on pharmacotherapy.
[92] J. Karlowsky,et al. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent , 2016, Drugs.
[93] J. Pagés,et al. Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam , 2015, Antimicrobial Agents and Chemotherapy.
[94] Akinobu Ito,et al. In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains , 2015, Antimicrobial Agents and Chemotherapy.
[95] A. Bolger,et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association , 2015, Circulation.
[96] S. Levy,et al. Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline , 2015, Antimicrobial Agents and Chemotherapy.
[97] M. Mahoney,et al. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. , 2015, International journal of antimicrobial agents.
[98] R. Frykberg,et al. Linezolid-Associated Serotonin Syndrome. A Report of Two Cases. , 2015, Journal of the American Podiatric Medical Association.
[99] S. Burdette,et al. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[100] H. Schweizer,et al. Efflux pump-mediated drug resistance in Burkholderia , 2015, Front. Microbiol..
[101] Craig A. Martin,et al. Early Experience with Tedizolid: Clinical Efficacy, Pharmacodynamics, and Resistance , 2014, Pharmacotherapy.
[102] G. Poce,et al. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development. , 2014, European journal of medicinal chemistry.
[103] Cheng‐He Zhou,et al. Novel hybrids of metronidazole and quinolones: synthesis, bioactive evaluation, cytotoxicity, preliminary antimicrobial mechanism and effect of metal ions on their transportation by human serum albumin. , 2014, European journal of medicinal chemistry.
[104] S. Gropper,et al. Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial. , 2014, Future microbiology.
[105] Ronald N. Jones,et al. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. , 2014, Diagnostic microbiology and infectious disease.
[106] Zhengyu Yuan,et al. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. , 2014, Journal of medicinal chemistry.
[107] T. Wichelhaus,et al. Novel promising linezolid analogues: rational design, synthesis and biological evaluation. , 2013, European journal of medicinal chemistry.
[108] D. Fong,et al. Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance , 2013, Front. Cell. Infect. Microbiol..
[109] Han Liu,et al. Total synthesis of daptomycin by cyclization via a chemoselective serine ligation. , 2013, Journal of the American Chemical Society.
[110] Ronald N. Jones,et al. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). , 2013, The Journal of antimicrobial chemotherapy.
[111] J. Karlowsky,et al. Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination , 2013, Drugs.
[112] D. Shlaes. New β‐lactam–β‐lactamase inhibitor combinations in clinical development , 2013, Annals of the New York Academy of Sciences.
[113] L. Mandell. Gemifloxacin , 2020, Drugs.
[114] Ronald N. Jones,et al. In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods , 2012, Antimicrobial Agents and Chemotherapy.
[115] S. Kondo,et al. Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections. , 2012, Auris, nasus, larynx.
[116] Heping Yang,et al. Prulifloxacin versus Levofloxacin in the Treatment of Respiratory and Urinary Tract Infections: A Multicentre, Double-Blind, Randomized Controlled Clinical Trial , 2012, Chemotherapy.
[117] Ronald N. Jones,et al. Disk Diffusion and MIC Quality Control Ranges for BC-3205 and BC-3781, Two Novel Pleuromutilin Antibiotics , 2012, Journal of Clinical Microbiology.
[118] Ronald N. Jones,et al. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). , 2012, The Journal of antimicrobial chemotherapy.
[119] Nicola G. Jones,et al. Synthesis and Structure − Activity Relationships of New Quinolone-Type Molecules against Trypanosoma brucei , 2012 .
[120] M. Rönn,et al. Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. , 2012, Journal of medicinal chemistry.
[121] Z. Aktaş,et al. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. , 2012, International journal of antimicrobial agents.
[122] J. Karlowsky,et al. Comparative Review of the Carbapenems , 2012, Drugs.
[123] L. Scott,et al. Besifloxacin Ophthalmic Suspension 0.6% , 2012, Drugs.
[124] A. Mahmoud,et al. Chapter 4 – Gemifloxacin , 2011 .
[125] C. Shim,et al. Fluorescence detection of Zabofloxacin, a novel fluoroquinolone antibiotic, in plasma, bile, and urine by HPLC: the first oral and intravenous applications in a pharmacokinetic study in rats. , 2011, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[126] A. Tolmachev,et al. Bicyclic conformationally restricted diamines. , 2011, Chemical reviews.
[127] F. Goh,et al. In Vitro Spectrum of Activity of Finafloxacin, a Novel, pH-Activated Fluoroquinolone, under Standard and Acidic Conditions , 2011, Antimicrobial Agents and Chemotherapy.
[128] E. Goldstein,et al. Activity of garenoxacin against 536 unusual anaerobes including 128 recovered from acute pelvic infections. , 2011, Diagnostic microbiology and infectious disease.
[129] M. Falagas,et al. Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections. , 2011, International journal of antimicrobial agents.
[130] C. Hutnik,et al. Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis , 2011, Ophthalmology and eye diseases.
[131] E. Chahine,et al. Doripenem: a new carbapenem antibiotic. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[132] Honggang Hu,et al. Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase. , 2010, European journal of medicinal chemistry.
[133] L. A. Feeney,et al. Synthesis and Spectrum of the Neoglycoside ACHN-490 , 2010, Antimicrobial Agents and Chemotherapy.
[134] Lian-Shun Feng,et al. Synthesis and in vitro antimycobacterial activity of balofloxacin ethylene isatin derivatives. , 2010, European journal of medicinal chemistry.
[135] Hee-Soo Park,et al. DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae. , 2010, International journal of antimicrobial agents.
[136] Steven D. Brown,et al. Comparative In Vitro Antimicrobial Activities of Torezolid (TR-700), the Active Moiety of a New Oxazolidinone, Torezolid Phosphate (TR-701), Determination of Tentative Disk Diffusion Interpretive Criteria, and Quality Control Ranges , 2010, Antimicrobial Agents and Chemotherapy.
[137] L. Xiao-dong,et al. The influence of a newly developed quinolone: Antoflox-acin, on CYP activity in rats , 2010, European Journal of Drug Metabolism and Pharmacokinetics.
[138] D. Hoban,et al. In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates , 2009, Antimicrobial Agents and Chemotherapy.
[139] C. Liao,et al. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. , 2009, The Journal of antimicrobial chemotherapy.
[140] Yong-hong Xiao,et al. Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection , 2008, Acta Pharmacologica Sinica.
[141] L. Piddock,et al. The Efflux Pump Inhibitor Reserpine Selects Multidrug-Resistant Streptococcus pneumoniae Strains That Overexpress the ABC Transporters PatA and PatB , 2008, Antimicrobial Agents and Chemotherapy.
[142] S. Deresinski,et al. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[143] D. Guay,et al. Update on clindamycin in the management of bacterial, fungal and protozoal infections , 2007, Expert opinion on pharmacotherapy.
[144] Daryl S Schiller,et al. Posaconazole: an extended-spectrum triazole antifungal agent. , 2007, Clinical therapeutics.
[145] Myung G. Lee,et al. Pharmacokinetics of DA‐7218, a new oxazolidinone, and its active metabolite, DA‐7157, after intravenous and oral administration of DA‐7218 and DA‐7157 to rats , 2007, The Journal of pharmacy and pharmacology.
[146] K. Ward,et al. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. , 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[147] A. Kwon,et al. In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. , 2006, The Journal of antimicrobial chemotherapy.
[148] J. Sobel,et al. Anidulafungin: a novel echinocandin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[149] Ronald N. Jones,et al. Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci , 2006, Antimicrobial Agents and Chemotherapy.
[150] Hee-Soo Park,et al. In Vitro and In Vivo Antibacterial Activities of DW-224a, a New Fluoronaphthyridone , 2006, Antimicrobial Agents and Chemotherapy.
[151] M. Jacobs,et al. Activity of Retapamulin against Streptococcus pyogenes and Staphylococcus aureus Evaluated by Agar Dilution, Microdilution, E-Test, and Disk Diffusion Methodologies , 2006, Antimicrobial Agents and Chemotherapy.
[152] M. Pfaller,et al. Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp , 2006, Journal of Clinical Microbiology.
[153] Telithromycin: A Possible Cause of Severe Liver Damage? , 2006, Annals of Internal Medicine.
[154] M. Cazzola,et al. Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis. , 2006, Pulmonary pharmacology & therapeutics.
[155] J. Schrenzel,et al. Intensive Therapy with Ceftobiprole Medocaril of Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.
[156] C. Perry,et al. Caspofungin: a review of its use in the treatment of fungal infections. , 2005, Drugs.
[157] Ronald N. Jones,et al. Activities of Doripenem (S-4661) against Drug-Resistant Clinical Pathogens , 2004, Antimicrobial Agents and Chemotherapy.
[158] B. Yoo,et al. Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections , 2004, The Annals of pharmacotherapy.
[159] A. Rodloff,et al. In Vitro Activity of OPT-80 against Clostridium difficile , 2004, Antimicrobial Agents and Chemotherapy.
[160] C. Carpenter,et al. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[161] B. Bozdoğan,et al. Oxazolidinones: activity, mode of action, and mechanism of resistance. , 2004, International journal of antimicrobial agents.
[162] T. Ishikawa,et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599 , 2004, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[163] Y. Ikeda,et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. , 2003, Bioorganic & medicinal chemistry.
[164] C. Perry,et al. Ertapenem: a review of its use in the management of bacterial infections. , 2003, Drugs.
[165] C. Perry,et al. Biapenem. , 2020, Drugs.
[166] M. Takahata,et al. Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids. Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756). , 2011, Arzneimittel-Forschung.
[167] J. Iqbal,et al. Synthesis of conformationally constrained analogues of linezolid: structure-activity relationship (SAR) studies on selected novel tricyclic oxazolidinones. , 2002, Journal of medicinal chemistry.
[168] K. Hayashi,et al. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. , 2002, The Journal of antimicrobial chemotherapy.
[169] Y. Kawai,et al. Photochemical behavior of sitafloxacin, fluoroquinolone antibiotic, in an aqueous solution. , 2002, Chemical & pharmaceutical bulletin.
[170] Antoine Andremont,et al. Bronchopulmonary Disposition of the Ketolide Telithromycin (HMR 3647) , 2001, Antimicrobial Agents and Chemotherapy.
[171] Marilyn Roberts,et al. Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance , 2001, Microbiology and Molecular Biology Reviews.
[172] E Rubinstein,et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[173] R. Jelliffe,et al. Comparative Pharmacokinetics and Pharmacodynamics of the Newer Fluoroquinolone Antibacterials , 2001, Clinical pharmacokinetics.
[174] H. Nagare,et al. [In vitro antimycobacterial activities of a new quinolone, balofloxacin]. , 2001, Kekkaku : [Tuberculosis].
[175] S. Douthwaite. Structure-activity relationships of ketolides vs. macrolides. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[176] V. Ramakrishnan,et al. The Structural Basis for the Action of the Antibiotics Tetracycline, Pactamycin, and Hygromycin B on the 30S Ribosomal Subunit , 2000, Cell.
[177] T. Tamaya,et al. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens. , 2000, The Journal of antimicrobial chemotherapy.
[178] H. Tomioka,et al. Comparative Antimicrobial Activities of the Newly Synthesized Quinolone WQ-3034, Levofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis andMycobacterium avium Complex , 2000, Antimicrobial Agents and Chemotherapy.
[179] R. Jones,et al. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. , 2000, Diagnostic microbiology and infectious disease.
[180] M. Hikida,et al. In Vitro Antibacterial Activity of LJC 11,036, an Active Metabolite of L-084, a New Oral Carbapenem Antibiotic with Potent Antipneumococcal Activity , 1999, Antimicrobial Agents and Chemotherapy.
[181] A. Yamada,et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. , 1999, The Journal of antibiotics.
[182] Yasuo Watanabe,et al. In Vitro and In Vivo Antimicrobial Activities of T-3811ME, a Novel Des-F(6)-Quinolone , 1999, Antimicrobial Agents and Chemotherapy.
[183] N. Jacobus,et al. In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9-t-Butylglycylamido Derivative of Minocycline (GAR-936) , 1999, Antimicrobial Agents and Chemotherapy.
[184] H. Narita,et al. Pharmacological properties of T-3762, a novel fluoroquinolone antimicrobial agent in parenteral use. III. Chemical structures and dermovascular permeability-increasing activities. , 1998, Biological & pharmaceutical bulletin.
[185] B. Pelak,et al. In Vivo Activity and Pharmacokinetic Evaluation of a Novel Long-Acting Carbapenem Antibiotic, MK-826 (L-749,345) , 1998, Antimicrobial Agents and Chemotherapy.
[186] Y. Kim,et al. Novel fluoroquinolone antibacterial agents containing oxime-substituted (aminomethyl)pyrrolidines: synthesis and antibacterial activity of 7-(4-(aminomethyl)-3-(methoxyimino)pyrrolidin-1-yl)-1-cyclopropyl-6- fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid (LB20304). , 1997, Journal of medicinal chemistry.
[187] J. Sobel,et al. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species , 1997, Antimicrobial agents and chemotherapy.
[188] J. Galgiani,et al. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts , 1997, Antimicrobial agents and chemotherapy.
[189] R. H. Baltz,et al. Gene transfer and transposition mutagenesis in Streptomyces roseosporus: mapping of insertions that influence daptomycin or pigment production. , 1996, Microbiology.
[190] M. Shaw,et al. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo , 1996, Antimicrobial agents and chemotherapy.
[191] Steven D. Brown,et al. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species , 1996, Antimicrobial agents and chemotherapy.
[192] S. J. Brickner,et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. , 1996, Journal of medicinal chemistry.
[193] A. Miyoshi,et al. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light , 1993, Antimicrobial Agents and Chemotherapy.
[194] T. Nishino,et al. In vivo evaluation of NM441, a new thiazeto-quinoline derivative , 1991, Antimicrobial Agents and Chemotherapy.
[195] M. Debono,et al. Deacylation of echinocandin B by Actinoplanes utahensis. , 1989, The Journal of antibiotics.
[196] K. Thomson,et al. Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases. , 1989, The Journal of antimicrobial chemotherapy.
[197] F. Kayser,et al. Activity of meropenem, against gram-positive bacteria. , 1989, The Journal of antimicrobial chemotherapy.
[198] H. Egger,et al. New pleuromutilin derivatives with enhanced antimicrobial activity.II.Structure-activity correlations. , 1976, The Journal of antibiotics.